Skip to main content
ENTA
NASDAQ Life Sciences

Enanta 10-K: $68.2M FY26 Loss, $194.5M Cash Funds Operations Into Fiscal 2029

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$8.99
Mkt Cap
$253.1M
52W Low
$8.605
52W High
$17.15
52W Position info
4.5% above low
Off High info
48% below high
Rel. Volume info
3.1× avg
Market data snapshot near publication time

ENTA is trading near its 52-week low of $8.605 (4.5% above the low) on elevated volume (3.1× avg).

Summary

Enanta's fiscal 2026 10-K shows a $68.2M net loss on $63.0M of royalty revenue, with $194.5M in cash and securities projected to fund operations into fiscal 2029. The report details the post-restructuring cost base and 2027 clinical readouts for zelicapavir.


Key Events · Earnings and Guidance · ENTA

  • Fiscal 2026 Loss Narrows to $68.2M

    Full-year net loss of $68.2M ($2.35 per share) on $63.0M of royalty revenue, versus an $81.9M loss on $65.3M in fiscal 2025.

  • Cash Runway Into Fiscal 2029

    $194.5M in cash, cash equivalents and marketable securities at September 30, 2026, plus the retained 45.5% of HCV royalties, is projected to fund operations into fiscal 2029; no going-concern qualification.

  • Cost Base Cut, Interest Expense Up

    R&D fell to $88.5M from $106.7M and G&A to $36.8M from $43.9M, while interest expense rose to $14.1M from $7.7M on higher forecast royalties owed to OMERS.

  • Zelicapavir Readouts Set for 2027

    RESOLVE Phase 2b/3 dosed its first patient in October 2026 with Phase 2b topline expected in 2027; LOTUS pediatric topline is expected in the first quarter of 2027.


Analysis · ENTA · Life Sciences

The annual report puts hard numbers on a shrinking business: royalty revenue slipped to $63.0M from $65.3M as AbbVie's HCV sales erode, and the company lost $68.2M for the year. What matters is the runway — $194.5M of cash and securities plus the retained 45.5% of HCV royalties is projected to carry Enanta into fiscal 2029, so there is no near-term financing emergency even with the $75M ATM sitting unused. The cost side has already been cut hard: R&D fell to $88.5M from $106.7M and headcount is down to 74 after the September reduction of roughly one-third. The offsetting drag is interest expense, which jumped to $14.1M from $7.7M because higher forecast MAVYRET/MAVIRET royalties flow to OMERS under the 2023 royalty sale. Pipeline timing is the swing factor: zelicapavir's RESOLVE Phase 2b data land in 2027 and LOTUS pediatric topline in 1Q 2027, while the STAT6 IND has slipped to 2Q 2027 on a manufacturing delay.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ENTA was trading at $8.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $253.1M. The 52-week trading range was $8.61 to $17.15. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ENTA - Latest Insights

ENTA
Nov 16, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.41
Real-time Price: $8.99 info
Change: -$1.42 (-14%) info
Market Cap: $253.1M info
ENTA
Nov 16, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $10.66
Real-time Price: $8.99 info
Change: -$1.67 (-16%) info
Market Cap: $253.1M info
ENTA
Oct 29, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.15
Real-time Price: $8.99 info
Change: -$2.16 (-19%) info
Market Cap: $253.1M info
ENTA
Oct 28, 2026, 7:14 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $11.99
Real-time Price: $8.99 info
Change: -$3.00 (-25%) info
Market Cap: $253.1M info
ENTA
Aug 12, 2026, 7:00 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $13.52
Real-time Price: $8.99 info
Change: -$4.53 (-34%) info
Market Cap: $253.1M info